Accelerating Biosimilar Uptake in the US Market: Barriers and Solutions
Journal of Clinical Pathways spoke with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, president of the Association of Community Cancer Centers (ACCC), regarding the reasons why oncology biosimilar uptake in the US has been a lengthy process and whether these products will be viable options for payer-based and provider-based clinical pathways in the future.
